HER2-positive neuroendocrine breast carcinoma: a case study uncovers CCND1, FGF19, and IGF1R amplifications as new molecular drivers
This study represents the first report of <i>CCND1</i>, <i>FGF19</i>, and <i>IGF1R</i> gene amplification in a breast neuroendocrine carcinoma. These findings provide new insights into the molecular profile of this entity and may contribute to future studies on precision oncology.
Authors
- Aldo Scarpa
- Alessia Nottegar (ORCID: https://orcid.org/0000-0003-3325-8705)
- Giulia Querzoli (ORCID: https://orcid.org/0000-0002-6944-6508)
- Valeria Maffeis (ORCID: https://orcid.org/0000-0002-8123-3724)
- Francesca Pellini (ORCID: https://orcid.org/0000-0002-2286-9060)
- Matteo Brunelli (ORCID: https://orcid.org/0000-0002-3832-2676)
- Margherita Zordan
- Andrea Mafficini
- Pamela Biondani
- Bianca Barioglio
- Alessandra Invento (ORCID: https://orcid.org/0000-0002-8185-8513)
- Elena Fiorio (ORCID: https://orcid.org/0000-0002-1354-4600)
- Claudio Luchini
Institutions
- University of Verona (IT)
- Ospedale Santa Chiara (IT)
- Azienda USL di Bologna (IT)
Publication Details
- Journal
- Pathologica
- Published
- 2025-10-01
- DOI
- https://doi.org/10.32074/1591-951x-n981
- Primary Topic
- Breast Lesions and Carcinomas
- Type
- article
- Field-Weighted Citation Impact
- 0.00